Smithkline Beecham Corporation

Boehringer Mannheim Pharmaceuticals Corporation

Smithkline Bechman Corporation Limited Partnership No. 1

Smithkline Beecham Corporation Limited Prtnrshp No. 1

Tian-Li Yue

Giora Zeev Feuerstein

Eliot H Ohlstein

Xinkang Wang

Frank C Barone

This invention relates to a method for inhibiting stress-activated protein kinases (SAPKs) which comprises administering to a mammal in need thereof an effective amount of a compound which is a dual non-selective &bgr;-adrenoceptor and &agr;,-adrenoceptor antagonist.

Method for inhibiting stress-activated protein kinases

Method for inhibiting the expression of Fas

This invention relates to a new antioxidant use of, and method of treatment using certain hydroxycarbazole compounds or a pharmaceutically acceptable salt thereof. More specifically, the compounds are useful for the prevention of oxidative tissue damage to organs, particularly the central nervous system including the brain, in mammals afflicted with disease-induced ischemic trauma, particularly stroke.

Antioxidant cardioprotective use of, and method of treatment using,

The present invention provides a new medical use of the hydroxycarbazole compounds of Formula (I), preferably the hydroxylated metabolites of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol)(carve dilol), for inhibiting the migration and proliferation of smooth muscle cells. In particular, the present invention provides a new use for the hydroxycarbazole compounds of Formula (I) for prevention of restenosis following percutaneous transluminal coronary angioplasty (PTCA), suppression of the progression of vascular hypertrophy associated with hypertension, and prevention of development of atherosclerosis. ##STR1## wherein: R.sub.1 -R.sub.9 are independently --H or --OH, with the proviso that a at least one of R.sub.1 -R.sub.9 is OH.

Use of, and method of treatment using, hydroxycarbazole compounds for

Growing community of inventors

Havertown, PA, United States of America

Tian-Li Yue